Lund, SE — August 12, 2025 — Leads & Copy — Cantargia will release its interim report for the first six months of 2025 on Thursday, August 21, 2025, at 07:00 a.m. CEST.
Cantargia is inviting investors, analysts, and media to an audiocast with teleconference on August 21, at 3:00 p.m. CEST. Interim CEO Damian Marron, CBO Ton Berkien, and CFO Patrik Renblad, will present Cantargia and comment on the report, followed by a Q&A-session.
To participate via audiocast, use this link: https://cantargia.events.inderes.com/q2-report-2025. Questions can be asked during the web session.
To participate via teleconference, register on the link below to receive phone numbers and a conference ID: https://events.inderes.com/cantargia/q2-report-2025/dial-in. Questions can be asked verbally via the teleconference.
The webcast will also be available on demand on Cantargia’s corporate website.
Cantargia AB (publ) develops antibody-based treatments for life-threatening diseases, focusing on cancer and inflammatory diseases. Its oncology program, nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy, with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Cantargia’s second development program, the antibody CAN10, addresses treatment of serious autoimmune/inflammatory diseases.
Damian Marron, Interim CEO
Telephone: +46 (0)46-275 62 60
E-mail: damian.marron@cantargia.com
Source: Cantargia
